8
Jan
2016

All the Biotech Deals and Financings You Can Grok Before JP Morgan 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On